-
Feb 1, 2025 | 
thehindubusinessline.com | PT Jyothi Datta
An expansion of Patient Assistance Programmes (PAP) is expected, with the Union Budget exempting 37 medicines from basic customs duty (BCD), provided the medicines are given free. Medicines from 10 multinational companies are listed in PAPs mentioned in the Budget. PAPs help soften the price-burden on patients, as expensive cancer and other critical drugs from these companies are provided to patients under arrangements – sometimes entirely free or at a reduced price or discount.
-
Feb 1, 2025 | 
thehindubusinessline.com | PT Jyothi Datta
Cancer patients, including those on patient assistance programmes, can look forward to some relief on their imported medicines.
-
Jan 31, 2025 | 
thehindubusinessline.com | PT Jyothi Datta
Sun Pharmaceutical Industries expects its total research spend to be shy of its guidance of 7 percent of sales for this financial year, top management said. The company continues to invest in its research and development pipeline for its specialty and generics business, said Dilip Shanghvi, Sun Pharma Chairman and Managing Director.
-
Jan 29, 2025 | 
thehindubusinessline.com | PT Jyothi Datta
Piramal Pharma is approaching the next few months with “cautious optimism”, given the geopolitical uncertainty and directives from the new administration in the United States. Customers continue to look for a diversified supply chain, said Nandini Piramal, Chairperson, Piramal Pharma,adding, “we have capacity available in the US across API (active pharmaceutical ingredients), formulations and we’re doing an upgrade and expansion of capacity in our Lexington facility for injectables.
-
Jan 29, 2025 | 
thehindubusinessline.com | PT Jyothi Datta
As more research is done on biological products, including cutting-edge cell and gene therapies, the clinical research industry hopes that Budget 2025 will extend more financial incentives to it.
-
Jan 28, 2025 | 
thehindubusinessline.com | PT Jyothi Datta
Drugmaker Cipla expects its “diversified” business in the US to help sustain its growth in the region, at a time the US administration is holding back funding for a global HIV/AIDS programme, besides looking at higher tariffs on imported pharmaceuticals, to strengthen local production.
-
Jan 27, 2025 | 
thehindubusinessline.com | PT Jyothi Datta
The Centre has sent a high-level multi-disciplinary team to Pune to support State health authorities in public health interventions and management of cases of Guillain Barre’ Syndrome (GBS) in Maharashtra. GB syndrome is an auto-immune neurological condition where the immune system attacks the peripheral nerves. Maharashtra has reported over 100 cases, including one suspected death, according to reports.
-
Jan 27, 2025 | 
thehindubusinessline.com | PT Jyothi Datta
Despite being home to 60 per cent of the global population, Asia accounts for only 22 per cent of global health care spending – opening an opportunity for innovation and technology to bridge the gap differently from the manner of “legacy” infrastructure, points out a recent Boston Consulting Group (BCG) report.
-
Jan 27, 2025 | 
flipboard.com | PT Jyothi Datta
Which States Could Survive on Their Own If They Seceded From the Union? Though it is unlikely that any U.S. state will secede from the union, it is certainly a possibility. If such a situation were to arise, it could be …
-
Jan 26, 2025 | 
thehindubusinessline.com | PT Jyothi Datta
The last several weeks have seen an increase in conversations around cell and gene therapies (CGT) in the country — the promise they hold as treatment, and the role India can play in making these products at a fraction of global cost. Cutting cost, without cutting corners, is how cancer physician and author Dr Siddhartha Mukherjee recently described the CAR-T journey at Immuneel Therapeutics.
